• CX-5461: RNA Polymerase I Inhibitor for Solid Tumor Research

  2026-05-09

  CX-5461 is redefining cancer research by enabling precise inhibition of Pol I-driven rRNA synthesis, offering a potent approach to study ribosome biogenesis and overcome chemoresistance. Its demonstrated synergy with cisplatin in cervical cancer models highlights advanced use-cases for targeting solid tumor growth and optimizing combination therapies.

• (S)-(+)-Dimethindene maleate for M2 Muscarinic Receptor Stud

  2026-05-08

  (S)-(+)-Dimethindene maleate provides selective antagonism of the M2 muscarinic acetylcholine receptor and H1 histamine receptor, supporting precise interrogation of autonomic and cardiovascular pathways. It is intended for controlled laboratory research, not for diagnostic or clinical use, and requires strict adherence to solubility and storage protocols to maintain integrity.

• Chloroquine (BA1002): Application and Best Practices in Rese

  2026-05-08

  Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) is a 4-aminoquinoline compound used as an anti-inflammatory agent for malaria research, as well as for studying autophagy and immune modulation. This product is suited for in vitro and in vivo research applications but requires careful adherence to solubility, dosing, and safety parameters. It is not recommended for clinical or translational studies without validated workflows and monitoring.

• GKT137831: Redefining Redox Modulation for Translational Res

  2026-05-07

  This thought-leadership article explores the mechanistic basis and translational strategy for using GKT137831, a dual NADPH oxidase Nox1/Nox4 inhibitor, to address oxidative stress-driven pathologies. Integrating evidence from recent cell biology advances and preclinical models, it provides guidance for experimental design, benchmarks its advantages against the competitive landscape, and projects future directions for redox-targeted interventions in vascular and fibrotic diseases.

• Clozapine in Schizophrenia Research: Protocols and Innovatio

  2026-05-07

  Explore how Clozapine, an atypical antipsychotic medication, is leveraged to dissect receptor signaling and neuroplasticity in advanced schizophrenia models. This guide delivers actionable protocols, troubleshooting strategies, and the latest insights from neuromodulation research—empowering neuroscientists to design robust, translational experiments.

• Disrupting c-MYC/G9a Axis: Co-Targeting BRD4 and RAC1 in Bre

  2026-05-06

  This study introduces a co-targeting approach inhibiting both BRD4 and RAC1, revealing suppression of breast cancer cell growth and stemness via disruption of the c-MYC-G9a-FTH1 axis and downregulation of HDAC1. The findings highlight a mechanistic link between chromatin modification and oncogenic signaling, providing a rationale for precision epigenetic intervention in heterogeneous breast cancer subtypes.

• Ampicillin Sodium: Precision Benchmarking for Antibacterial

  2026-05-06

  Explore the scientific rigor and precision benchmarking of Ampicillin sodium, a β-lactam antibiotic, in advanced antibacterial activity assays. This article uniquely dissects comparative data, assay optimization, and best practices for translational research.

• AMPK-JAK2/STAT3 Axis Modulates M1 Macrophages in Obesity-Lin

  2026-05-05

  This study elucidates how AMPK downregulation drives M1 macrophage polarization and airway inflammation in obesity-related asthma, revealing the JAK2/STAT3 pathway as a mechanistic link. The findings clarify therapeutic opportunities for targeting metabolic-inflammation crosstalk in severe, steroid-resistant asthma.

• NU7441 (KU-57788): Selective DNA-PK Inhibition for DNA Repai

  2026-05-05

  NU7441 (KU-57788) is a potent, selective ATP-competitive DNA-PK inhibitor, essential for dissecting DNA repair and oncology pathways. It achieves nanomolar inhibition with minimal off-target activity and is widely adopted in cell cycle and cancer research. NU7441 enables precise modulation of DNA damage responses in both in vitro and in vivo models.

• Fludarabine as a DNA Synthesis Inhibitor: Oncology Workflows

  2026-05-04

  Fludarabine stands out as a rigorously validated DNA synthesis inhibitor, enabling precise manipulation of cell cycle arrest and apoptosis in leukemia and multiple myeloma research. Recent breakthroughs show it can also remodel tumor antigenicity, unlocking synergy with immunotherapies. This guide translates the latest experimental findings into actionable workflows, troubleshooting, and advanced use-cases.

• Penicillin G Sodium: Applied Workflows for Research Excellen

  2026-05-04

  Penicillin G Sodium stands at the forefront of research-grade antibiotics, offering precise inhibition of bacterial cell wall biosynthesis for robust experimental control. This guide unpacks actionable workflows, troubleshooting insights, and strategic advantages that make APExBIO’s Penicillin G Sodium an essential tool for infection modeling and contamination prevention.

• Cy7 NHS Ester: Practical Guide for Near-Infrared Biomolecule

  2026-05-03

  Cy7 NHS ester addresses the challenge of water-soluble, non-quenching fluorescent labeling for proteins and peptides, especially sensitive to denaturation. Its sulfonated structure supports reliable near-infrared imaging in live and complex systems. Use is not recommended where long-term dye solutions or organic solvent-based labeling are required.

• SP2509 (B4894): Reliable LSD1 Antagonist for AML Epigenetics

  2026-05-02

  This article addresses key challenges in AML research workflows, focusing on how SP2509 (SKU B4894) provides reproducible, data-backed solutions for cell viability and epigenetic modulation assays. Scenario-driven Q&A blocks offer evidence-based guidance on protocol optimization, data interpretation, and vendor selection, supporting the needs of biomedical researchers and lab technicians seeking robust results in cancer epigenetics.

• Ceftazidime: Advanced Protocols and Resistance Dynamics in G

  2026-05-01

  Explore Ceftazidime—a third-generation cephalosporin—in the context of modern resistance dynamics and advanced laboratory protocols. This article offers a unique, evidence-driven guide for researchers tackling Gram-negative infections, with deep insights into carbapenemase transmission and practical assay optimization.

• Metabolomics Reveals Biomarkers of Carbapenem Resistance in

  2026-05-01

  The referenced study demonstrates that LC-MS/MS metabolomics can rapidly distinguish carbapenemase-producing Enterobacterales (CPE) from non-CPE strains by identifying unique metabolic biomarkers. These findings pave the way for faster, more precise diagnostic assays and enhance understanding of resistance phenotypes, with significant implications for antibiotic resistance research and clinical practice.

16304 records 1/1087 page Next 12345 下5页 Last page